Samay Information

Samay has cracked the code on respiratory diagnostics with Sylvee—our AI-enabled chest sensor that outperforms existing tools by 2x. Protected by 12 patents and backed by $5M+ from NSF, NIH, VCs, and pharma partners, Sylvee achieves breakthrough accuracy: 90%+ precision in COPD detection and 80% accuracy in air trapping identification. Our integrated platform delivers what the market desperately needs: early COPD diagnosis, continuous remote monitoring, and biomarker discovery for 550+ million patients worldwide—80% of whom remain undiagnosed. The impact? Preventing millions of premature deaths while reducing the $143B annual COPD expenses through partnerships with healthcare systems and pharmaceutical companies.